A detailed history of Price T Rowe Associates Inc transactions in Spring Works Therapeutics, Inc. stock. As of the latest transaction made, Price T Rowe Associates Inc holds 3,516,418 shares of SWTX stock, worth $132 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
3,516,418
Previous 3,602,234 2.38%
Holding current value
$132 Million
Previous $136 Million 16.97%
% of portfolio
0.01%
Previous 0.02%

Shares

16 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$32.04 - $42.76 $2.75 Million - $3.67 Million
-85,816 Reduced 2.38%
3,516,418 $113 Million
Q2 2024

Aug 14, 2024

SELL
$36.06 - $47.62 $18.3 Million - $24.2 Million
-508,228 Reduced 12.36%
3,602,234 $136 Million
Q1 2024

May 15, 2024

BUY
$36.5 - $52.5 $48.7 Million - $70 Million
1,333,892 Added 48.04%
4,110,462 $202 Million
Q4 2023

Feb 14, 2024

BUY
$18.94 - $37.24 $23.1 Million - $45.5 Million
1,221,056 Added 78.5%
2,776,570 $101 Million
Q3 2023

Nov 14, 2023

BUY
$23.12 - $31.38 $4.97 Million - $6.74 Million
214,884 Added 16.03%
1,555,514 $36 Million
Q2 2023

Aug 14, 2023

BUY
$23.15 - $32.71 $24.7 Million - $34.9 Million
1,067,203 Added 390.31%
1,340,630 $35.2 Million
Q1 2023

May 15, 2023

BUY
$24.97 - $34.05 $868,306 - $1.18 Million
34,774 Added 14.57%
273,427 $7.04 Million
Q4 2022

Feb 14, 2023

SELL
$21.73 - $28.72 $221,689 - $293,001
-10,202 Reduced 4.1%
238,653 $6.21 Million
Q3 2022

Nov 14, 2022

BUY
$24.1 - $39.66 $178,629 - $293,959
7,412 Added 3.07%
248,855 $7.1 Million
Q2 2022

Aug 15, 2022

SELL
$18.36 - $60.07 $1.36 Million - $4.45 Million
-73,999 Reduced 23.46%
241,443 $5.94 Million
Q1 2022

May 16, 2022

BUY
$48.97 - $65.46 $166,546 - $222,629
3,401 Added 1.09%
315,442 $17.8 Million
Q4 2021

Feb 14, 2022

BUY
$53.3 - $75.84 $246,992 - $351,442
4,634 Added 1.51%
312,041 $19.3 Million
Q3 2021

Nov 15, 2021

SELL
$62.66 - $88.26 $95,869 - $135,037
-1,530 Reduced 0.5%
307,407 $19.5 Million
Q2 2021

Aug 16, 2021

SELL
$67.45 - $85.63 $1.26 Million - $1.6 Million
-18,742 Reduced 5.72%
308,937 $25.5 Million
Q1 2021

May 17, 2021

BUY
$65.1 - $93.59 $97,584 - $140,291
1,499 Added 0.46%
327,679 $24.1 Million
Q4 2020

Feb 16, 2021

BUY
$48.36 - $77.92 $15.8 Million - $25.4 Million
326,180 New
326,180 $23.7 Million

Others Institutions Holding SWTX

About SpringWorks Therapeutics, Inc.


  • Ticker SWTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 62,401,100
  • Market Cap $2.34B
  • Description
  • SpringWorks Therapeutics, Inc. acquires, develops, and commercializes medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is nirogacestat, an oral small molecule gamma secretase inhibitor that is in Phase III clinical trial for the treatment of desmoid tumors. The company is also deve...
More about SWTX
Track This Portfolio

Track Price T Rowe Associates Inc Portfolio

Follow Price T Rowe Associates Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Price T Rowe Associates Inc , based on Form 13F filings with the SEC.

News

Stay updated on Price T Rowe Associates Inc with notifications on news.